Dr. Rana McKay on practice-changing trials in advanced renal cell carcinoma

The study achieved 100% local control and cancer-specific mortality rates with stereotactic ablative body radiotherapy.

The supplemental new drug application is supported by findings from the LITESPARK-005 trial.

The phase 1/2 Oncorella-1 trial is expected to enroll up to 40 patients with advanced kidney cancer who are on dialysis due to renal failure.

A Cleveland Clinic study found that TKIs in the neoadjuvant setting are associated with greater use of partial nephrectomy when treating patients diagnosed with renal masses in a solitary kidney.

The disease-free survival and distant metastasis-free survival benefits observed with adjuvant pembrolizumab in the intent-to-treat population of patients with clear cell renal cell carcinoma extended across all subgroups defined by disease risk, tumor stage, and lymph node involvement.

Patients in the phase 3 LITESPARK-005 trial were randomized to belzutifan or everolimus after receiving both a PD-1/L1 inhibitor and a VEGF-TKI for their renal cell carcinoma.